ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder
15 juil. 2024 07h00 HE
|
ANI Pharmaceuticals, Inc.
PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug...
ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP
02 juil. 2024 07h00 HE
|
ANI Pharmaceuticals, Inc.
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for...
ANI Pharmaceuticals’ CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award Winner
25 juin 2024 07h00 HE
|
ANI Pharmaceuticals, Inc.
PRINCETON, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that its Chief Executive Officer, Nikhil Lalwani, has been named an...
ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences
24 juin 2024 06h50 HE
|
ANI Pharmaceuticals, Inc.; Alimera Sciences, Inc.
Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded...
ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare Conference
29 mai 2024 16h30 HE
|
ANI Pharmaceuticals, Inc.
BAUDETTE, Minn., May 29, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2024...
ANI Pharmaceuticals Announces the Launch of Kionex® Suspension
20 mai 2024 06h50 HE
|
ANI Pharmaceuticals, Inc.
BAUDETTE, Minn., May 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Kionex® (Sodium Polystyrene Sulfonate Suspension USP)...
ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance
10 mai 2024 06h50 HE
|
ANI Pharmaceuticals, Inc.
Generated record quarterly net revenues of $137.4 million, representing year-over-year growth of 28.7%, net income to common shareholders of $17.8 million, and GAAP diluted earnings per share of...
ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences
01 mai 2024 16h30 HE
|
ANI Pharmaceuticals, Inc.
BAUDETTE, Minn., May 01, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief...
ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET
18 avr. 2024 16h05 HE
|
ANI Pharmaceuticals, Inc.
BAUDETTE, Minn., April 18, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2024 financial...
ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension
09 avr. 2024 06h50 HE
|
ANI Pharmaceuticals, Inc.
BAUDETTE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Baclofen Oral Suspension, a generic version of the...